BioCentury
ARTICLE | Preclinical News

Inhibiting IDO could slow TB disease progression

December 20, 2017 12:05 AM UTC

In a paper published in the Proceedings of the National Academy of Sciences, researchers at Tulane University School of Medicine and colleagues found that inhibiting indoleamine 2,3-dioxygenase (IDO; INDO) could slow tuberculosis disease progression, suggesting a new target to treat the disease.

The research identified a correlation between indoleamine 2,3-dioxygenase 1 (IDO1) expression and Mycobacterium tuberculosis bacterial count -- particularly within inflamed tissue masses called granulomas where the presence of IDO might prevent T cells and B cells from reaching infected phagocytes -- in the lungs of mouse and macaque models of TB infection...